STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial

Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit compared to a sham treatment in a Phase 3 trial.

STAT2 hr ago

Published by CurrentWire Sep 2, 2026 at 5:00 PM ET · First coverage Sep 2, 2026 at 4:37 PM ET

Compiled by CurrentWire News Desk

Summary based on reporting from STAT.

STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial

Read the full report at STAT

X Facebook LinkedIn Email

Automated coverage analysis

Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.

Source mix

1 independent editorial domain

What coverage breadth measures

Coverage

1 publication is covering this story.

STATTier B
STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial(opens original report in a new tab)2 hr ago

How CurrentWire compiled this story

STAT (www.statnews.com), a Tier B publisher, filed this report on Sep 2, 2026 at 4:37 PM ET. CurrentWire published this page 23 minutes later, on Sep 2, 2026 at 5:00 PM ET.

Signal breakdown

CurrentWire ranked this story 57.8 of 100 in the snapshot this page was rendered from.

Freshness: 28.3 of 35
Source authority: 14 of 20
Coverage breadth: 4 of 20
Geographic relevance: 3.5 of 10
Story prominence: 8 of 10
Velocity: 0 of 5

Strongest signal: freshness, 28.3 of 35. How each signal is calculated.

Filed under Health · International · News.

CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.